After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

Sun Pharmaceutical Industries Ltd, which has been embroiled in a patent lawsuit in the US since last year over its specialty drug Leqselvi, received a favourable ruling from a court, paving the ...

Sun Pharma had appealed against the District of New Jersey’s decision that had previously granted a preliminary injunction delaying its launch of Leqselvi (deuruxolitinib) in the United States.

Sun Pharmaceuticals Industries Ltd on Thursday, April 10 said the US Court of Appeals for the Federal Circuit has ruled in ...

Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...

Sun Pharmaceutical Industries Ltd on Thursday said a US court has ruled in its favour and vacated a preliminary injunction ...

The injunction had temporarily barred Sun Pharma from launching Leqselvi in the United States due to an ongoing legal battle with Incyte Corporation. The appellate court's decision, which came shortly ...

US Court vacates injunction, allowing Sun Pharma to launch Leqselvi Emkay Global suggests a royalty-based settlement with Incyte Leqselvi's US sales projected at $40 million in FY26, $124 million ...

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma’s sales in the financial year 2026 (FY26), and $125 million in FY27. Sun Pharma said it will disclose ...